deferoxamine has been researched along with Liver Cirrhosis in 84 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 8.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "All of 34 patients with untreated hemochromatosis had distinctly elevated values for deferoxamine-chelatable iron." | 5.26 | Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload. ( Baggenstoss, AH; Baldus, WP; Dickson, ER; Fairbanks, VF, 1978) |
| "Deferiprone is an orally active iron-chelating agent that is being evaluated as a treatment for iron overload in thalassemia major." | 5.08 | Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. ( Brittenham, GM; Burt, AD; Cameron, RG; Fleming, KA; McClelland, RA; McLaren, CE; Olivieri, NF; Templeton, DM, 1998) |
| "The role of the orally active iron (Fe) chelator deferiprone in the treatment of beta-thalassemia remains a controversial subject." | 4.81 | The controversial role of deferiprone in the treatment of thalassemia. ( Richardson, DR, 2001) |
| "Deferiprone (L1) is an orally active iron-chelation agent that is being evaluated as a treatment for iron overload in thalassemia major." | 3.73 | Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. ( Peng, CT; Tsai, CH; Wu, KH; Wu, SF, 2006) |
| "Sixteen patients (age range, 3 to 17 years) with transfusion-dependent beta-thalassemia major were studied prospectively, beginning at the onset of chelation therapy with deferoxamine (desferrioxamine)." | 3.67 | A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study. ( Gonzalez-Crussi, F; Honig, GR; Ingrisano, C; Lloyd-Still, JD; Maurer, HS, 1988) |
| "Adult patients with transfusional hemosiderosis were given ascorbic acid and treated with the iron chelator, desferrioxamine B." | 3.65 | Treatment of iron overload in adults with continuous parenteral desferrioxamine. ( Bunn, HF; Cooper, B; Moloney, WC; Nathan, DG; Propper, RD; Rosenthal, DS, 1977) |
| "Hemochromatosis is a syndrome which, when fully expressed, is manifested by melanoderma , diabetes mellitus, and liver cirrhosis, with iron overload involving parenchymal and reticuloendothelial cells in many organ systems." | 2.36 | Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy. ( Kellermeyer, RW; McLaren, GD; Muir, WA, 1983) |
| "Furthermore, NAFLD patients with hepatic RES iron deposition had increased hepatic gene expression levels of M1 markers, IL-6, IL-1β, and CD40 and reduced gene expression of an M2 marker, TGM2, relative to patients with hepatocellular iron deposition pattern." | 1.51 | Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. ( Boukhar, S; Gochanour, E; Handa, P; Kowdley, KV; Maliken, BD; Morgan-Stevenson, V; Thomas, S; Yeh, MM, 2019) |
| "Liver fibrosis is the principal cause of morbidity and mortality in patients with iron overload." | 1.43 | Calcium channel blockers ameliorate iron overload-associated hepatic fibrosis by altering iron transport and stellate cell apoptosis. ( Chang, Y; Chu, L; Chu, X; Gao, Y; Guo, H; Liu, Z; Wang, N; Zhang, J; Zhang, X; Zhang, Y; Zhao, X, 2016) |
| "Liver fibrosis was additionally suppressed in the bile-duct ligation model by ID." | 1.35 | Attenuation of acute and chronic liver injury in rats by iron-deficient diet. ( Ikeda, K; Kawada, N; Nakajima, Y; Nakatani, K; Ogawa, T; Otogawa, K; Shiga, R, 2008) |
| "Treatment of patients with beta-thalassemia major has improved dramatically during the past 40 years; however, the current clinical status of these patients remains poorly characterized." | 1.32 | Complications of beta-thalassemia major in North America. ( Cohen, AR; Cunningham, MJ; Macklin, EA; Neufeld, EJ, 2004) |
| "Type 3 hemochromatosis is a rare autosomal recessive disorder due to mutations of the TFR2 gene." | 1.32 | Type 3 hemochromatosis and beta-thalassemia trait. ( Arosio, C; Bovo, G; Mariani, R; Pelucchi, S; Piperno, A; Riva, A; Salvioni, A; Vergani, A, 2004) |
| "In acute B19 parvovirus infections an underlying hematologic disease should be excluded." | 1.31 | [An older female patient with refractory anemia and hemochromatosis]. ( Ceconi, C; Fabel, H; Flemming, P; Schuppert, F; Sutor, GC; Wysk, J, 2002) |
| "Juvenile hemochromatosis is a rare genetic disorder that causes iron overload." | 1.31 | Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin. ( Brunello, F; Camaschella, C; De Gobbi, M; Mazza, U; Paccotti, P; Pasquero, P, 2000) |
| "6 patients who developed liver cirrhosis before or after their thalassemia was cured by bone marrow transplantation (age at transplantation, 11 to 25 years)." | 1.31 | Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. ( Angelucci, E; Lucarelli, G; Muretto, P, 2002) |
| "Risk factors associated with IDDM and IGT were lack of compliance with chelation therapy, iron overload and the presence of cirrhosis and severe fibrosis." | 1.30 | Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients. ( De Sanctis, V; Fortini, M; Gamberini, MR; Gilli, G; Testa, MR, 1998) |
| "The liver iron content of patients with liver cirrhosis was within the normal range." | 1.27 | Comparison between serum ferritin and computed tomographic densities of liver, spleen, kidney and pancreas in beta-thalassaemia major. ( Babiker, MA; Hafeez, MH; Karrar, ZA; Patel, PJ, 1987) |
| "All of 34 patients with untreated hemochromatosis had distinctly elevated values for deferoxamine-chelatable iron." | 1.26 | Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload. ( Baggenstoss, AH; Baldus, WP; Dickson, ER; Fairbanks, VF, 1978) |
| "Idiopathic hemochromatosis is an iron-storage disease more common in men than in women." | 1.26 | Idiopathic hemochromatosis: case report of a patient presenting with neurologic symptoms. ( Afrooz, N; Sinclair, WP, 1977) |
| "One case of transfusion haemochromatosis with haemolytic anaemia and renal failure gave an Fv value of 8,019 mug." | 1.24 | Differential ferrioxamine test in idiopathic haemochromatosis and transfusional haemosiderosis. ( Brunström, GM; Fielding, J; O'Shaughnessy, MC, 1966) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 49 (58.33) | 18.7374 |
| 1990's | 6 (7.14) | 18.2507 |
| 2000's | 16 (19.05) | 29.6817 |
| 2010's | 12 (14.29) | 24.3611 |
| 2020's | 1 (1.19) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, KM | 1 |
| Cho, SS | 1 |
| Ki, SH | 1 |
| Biliotti, E | 1 |
| Palazzo, D | 1 |
| Serani, M | 1 |
| Silvestri, AM | 1 |
| Volpicelli, L | 1 |
| Esvan, R | 1 |
| Franchi, C | 1 |
| Spaziante, M | 1 |
| Sorrentino, F | 1 |
| Taliani, G | 1 |
| Abdelgelil, NH | 1 |
| Abdellatif, MZM | 1 |
| Abdel-Hafeez, EH | 1 |
| Belal, US | 1 |
| Mohamed, RM | 1 |
| Abdel-Razik, AH | 1 |
| Hassanin, KMA | 1 |
| Abdel-Wahab, A | 1 |
| Handa, P | 1 |
| Thomas, S | 1 |
| Morgan-Stevenson, V | 1 |
| Maliken, BD | 1 |
| Gochanour, E | 1 |
| Boukhar, S | 1 |
| Yeh, MM | 1 |
| Kowdley, KV | 1 |
| Shvedova, AA | 1 |
| Kisin, ER | 1 |
| Murray, AR | 1 |
| Mouithys-Mickalad, A | 1 |
| Stadler, K | 1 |
| Mason, RP | 1 |
| Kadiiska, M | 1 |
| Dessì, C | 1 |
| Leoni, G | 1 |
| Moi, P | 1 |
| Danjou, F | 1 |
| Follesa, I | 1 |
| Foschini, ML | 1 |
| Morittu, M | 1 |
| Zappu, A | 1 |
| Defraia, E | 1 |
| Bina, P | 1 |
| Cunico, A | 1 |
| Civolani, A | 1 |
| Podda, RA | 1 |
| Origa, R | 1 |
| Darwish, SF | 1 |
| El-Bakly, WM | 2 |
| El-Naga, RN | 1 |
| Awad, AS | 1 |
| El-Demerdash, E | 2 |
| Zhang, Y | 2 |
| Zhao, X | 1 |
| Chang, Y | 1 |
| Chu, X | 1 |
| Zhang, X | 1 |
| Liu, Z | 1 |
| Guo, H | 1 |
| Wang, N | 1 |
| Gao, Y | 1 |
| Zhang, J | 1 |
| Chu, L | 1 |
| Mohammed, A | 1 |
| Abd Al Haleem, EN | 1 |
| Cerchione, C | 1 |
| Cerciello, G | 1 |
| Avilia, S | 1 |
| Della Pepa, R | 1 |
| Pugliese, N | 1 |
| Picardi, M | 1 |
| Catalano, L | 1 |
| Pane, F | 1 |
| Gumus, E | 1 |
| Abbasoglu, O | 1 |
| Tanyel, C | 1 |
| Gumruk, F | 1 |
| Ozen, H | 1 |
| Yuce, A | 1 |
| Adamkiewicz, TV | 1 |
| Abboud, MR | 1 |
| Paley, C | 1 |
| Olivieri, N | 1 |
| Kirby-Allen, M | 1 |
| Vichinsky, E | 1 |
| Casella, JF | 1 |
| Alvarez, OA | 1 |
| Barredo, JC | 1 |
| Lee, MT | 1 |
| Iyer, RV | 1 |
| Kutlar, A | 1 |
| McKie, KM | 1 |
| McKie, V | 1 |
| Odo, N | 1 |
| Gee, B | 1 |
| Kwiatkowski, JL | 1 |
| Woods, GM | 1 |
| Coates, T | 1 |
| Wang, W | 1 |
| Adams, RJ | 1 |
| Inati, A | 1 |
| Musallam, KM | 1 |
| Wood, JC | 1 |
| Taher, AT | 1 |
| Fragatou, S | 1 |
| Tsourveloudis, I | 1 |
| Manesis, G | 1 |
| Sutor, GC | 1 |
| Ceconi, C | 1 |
| Flemming, P | 1 |
| Wysk, J | 1 |
| Fabel, H | 1 |
| Schuppert, F | 1 |
| WOEHLER, F | 1 |
| WALSH, JR | 2 |
| MASS, RE | 2 |
| SMITH, FW | 2 |
| LANGE, V | 2 |
| MARCACCI, M | 1 |
| CICALA, P | 1 |
| GUIDONE, M | 1 |
| NAPPI, L | 1 |
| DIMARTINO, G | 1 |
| BETETTO, D | 1 |
| CRISTINA, P | 1 |
| CAPPELLETTI, S | 1 |
| SCOVILLE, B | 1 |
| BORCHERS, HG | 1 |
| SCHAUER, A | 1 |
| SCURO, LA | 1 |
| BROCCIA, G | 1 |
| DOBRILLA, G | 1 |
| TAGLIAMONTE, A | 1 |
| VENTURA, S | 1 |
| COLI, L | 1 |
| MOESCHLIN, S | 1 |
| SCHNIDER, U | 1 |
| WEILL, JP | 1 |
| SCHIRARDIN, H | 1 |
| ARBOGAST, J | 1 |
| BERTHIER, G | 1 |
| ALBAHARY, C | 1 |
| SCHNACK, H | 1 |
| WEWALKA, F | 1 |
| Cunningham, MJ | 1 |
| Macklin, EA | 1 |
| Neufeld, EJ | 1 |
| Cohen, AR | 1 |
| Riva, A | 1 |
| Mariani, R | 1 |
| Bovo, G | 1 |
| Pelucchi, S | 1 |
| Arosio, C | 1 |
| Salvioni, A | 1 |
| Vergani, A | 1 |
| Piperno, A | 1 |
| Berdoukas, V | 1 |
| Bohane, T | 1 |
| Tobias, V | 1 |
| De Silva, K | 1 |
| Fraser, I | 1 |
| Aessopos, A | 1 |
| Lindeman, R | 1 |
| Piga, A | 1 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Gaziev, J | 1 |
| Sodani, P | 1 |
| Polchi, P | 3 |
| Andreani, M | 1 |
| Lucarelli, G | 4 |
| Meo, A | 1 |
| Ruggeri, A | 1 |
| La Rosa, MA | 1 |
| Zanghì, L | 1 |
| Morabito, N | 1 |
| Duca, L | 1 |
| Wu, SF | 1 |
| Peng, CT | 1 |
| Wu, KH | 1 |
| Tsai, CH | 1 |
| Otogawa, K | 1 |
| Ogawa, T | 1 |
| Shiga, R | 1 |
| Nakatani, K | 1 |
| Ikeda, K | 1 |
| Nakajima, Y | 1 |
| Kawada, N | 1 |
| Williams, R | 2 |
| Cohen, A | 1 |
| Witzleben, C | 1 |
| Schwartz, E | 1 |
| McLaren, GD | 1 |
| Muir, WA | 1 |
| Kellermeyer, RW | 1 |
| Halliday, JW | 1 |
| Bassett, ML | 1 |
| Angelucci, E | 3 |
| Baronciani, D | 2 |
| Giardini, C | 2 |
| Galimberti, M | 2 |
| Martinelli, F | 1 |
| Baldassarri, M | 1 |
| Muretto, P | 3 |
| Swartz, RD | 1 |
| Legault, DJ | 1 |
| Ripalti, M | 1 |
| Erer, B | 1 |
| Gaziev, D | 1 |
| Olivieri, NF | 1 |
| Brittenham, GM | 1 |
| McLaren, CE | 1 |
| Templeton, DM | 1 |
| Cameron, RG | 1 |
| McClelland, RA | 1 |
| Burt, AD | 1 |
| Fleming, KA | 1 |
| Stella, M | 1 |
| Pinzello, G | 1 |
| Maggio, A | 1 |
| Gamberini, MR | 1 |
| Fortini, M | 1 |
| Gilli, G | 1 |
| Testa, MR | 1 |
| De Sanctis, V | 1 |
| De Gobbi, M | 1 |
| Pasquero, P | 1 |
| Brunello, F | 1 |
| Paccotti, P | 1 |
| Mazza, U | 1 |
| Camaschella, C | 1 |
| Pippard, MJ | 1 |
| Weatherall, DJ | 1 |
| Richardson, DR | 1 |
| Li, CK | 1 |
| Chik, KW | 1 |
| Lam, CW | 1 |
| To, KF | 1 |
| Yu, SC | 1 |
| Lee, V | 1 |
| Shing, MM | 1 |
| Cheung, AY | 1 |
| Yuen, PM | 1 |
| Cooper, B | 1 |
| Bunn, HF | 1 |
| Propper, RD | 1 |
| Nathan, DG | 1 |
| Rosenthal, DS | 1 |
| Moloney, WC | 1 |
| Baldus, WP | 1 |
| Fairbanks, VF | 1 |
| Dickson, ER | 1 |
| Baggenstoss, AH | 1 |
| Di Lollo, F | 1 |
| Morini, PL | 1 |
| Fazzini, G | 1 |
| Niosi, L | 1 |
| Sinclair, WP | 1 |
| Afrooz, N | 1 |
| Risdon, RA | 2 |
| Barry, M | 2 |
| Flynn, DM | 3 |
| Aldouri, MA | 1 |
| Wonke, B | 1 |
| Hoffbrand, AV | 1 |
| Laulicht, M | 1 |
| Fenton, LA | 1 |
| Scheuer, PJ | 1 |
| Kibbler, CC | 1 |
| Allwood, CA | 1 |
| Brown, D | 1 |
| Maurer, HS | 1 |
| Lloyd-Still, JD | 1 |
| Ingrisano, C | 1 |
| Gonzalez-Crussi, F | 1 |
| Honig, GR | 1 |
| Babiker, MA | 1 |
| Patel, PJ | 1 |
| Karrar, ZA | 1 |
| Hafeez, MH | 1 |
| Smith, PM | 1 |
| Studley, F | 1 |
| MacDonald, RA | 1 |
| MacSween, RN | 1 |
| Pechet, GS | 1 |
| Bohne, F | 1 |
| Harmuth-Hoene, AE | 1 |
| Weber, KM | 1 |
| Schimmelpfennig, W | 1 |
| Wagner, K | 1 |
| Schneider, G | 1 |
| Zimmermann, HB | 1 |
| Giorgio, AJ | 1 |
| Letsky, EA | 1 |
| Sakić, D | 1 |
| Zlatar, P | 1 |
| Stromeyer, G | 1 |
| Turbina, NS | 1 |
| Pergola, F | 1 |
| Matthes, KJ | 1 |
| Wöhler, F | 1 |
| Delaloye, B | 1 |
| Magnenat, P | 1 |
| Blanc, B | 2 |
| Harker, LA | 1 |
| Funk, DD | 1 |
| Finch, CA | 1 |
| Fainshtein, FE | 1 |
| Trubina, NS | 1 |
| Sobaleva, IuG | 1 |
| Rozanova, NS | 1 |
| Voronina, AN | 1 |
| Herreros, V | 1 |
| De Castro, S | 1 |
| Marañón, A | 1 |
| López Lara, F | 1 |
| Dávila, A | 1 |
| Cumming, RL | 1 |
| Millar, JA | 1 |
| Smith, JA | 1 |
| Goldberg, A | 1 |
| Fielding, J | 1 |
| O'Shaughnessy, MC | 1 |
| Brunström, GM | 1 |
| Losowsky, MS | 1 |
| Ploem, JE | 1 |
| de Wael, J | 1 |
| Verloop, MC | 1 |
| Punt, K | 1 |
| Brodanová, M | 1 |
| Hoenig, V | 1 |
| Vannotti, A | 1 |
| Aron, E | 2 |
| Weill, JD | 2 |
| Jobard, P | 1 |
| Galand, A | 2 |
| Domenech, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000592] | Phase 3 | 0 participants | Interventional | 1994-07-31 | Completed | ||
| [NCT00006182] | Phase 3 | 0 participants | Interventional | 2000-07-31 | Completed | ||
| Thalassemia Clinical Research Network (TCRN)[NCT00000623] | 1,000 participants (Anticipated) | Observational | 2000-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for deferoxamine and Liver Cirrhosis
| Article | Year |
|---|---|
Emerging roles of ferroptosis in liver pathophysiology.
Topics: Animals; Antineoplastic Agents; Caffeic Acids; Carcinoma, Hepatocellular; Cycloheximide; Cyclohexyla | 2020 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
Treatment of iron overload.
Topics: Bloodletting; Carcinoma, Hepatocellular; Deferoxamine; Hemochromatosis; Humans; Liver; Liver Cirrhos | 1984 |
Iron overload disorders: natural history, pathogenesis, diagnosis, and therapy.
Topics: Anemia, Hypochromic; Biological Transport; Bloodletting; Chelating Agents; Deferoxamine; Disease Mod | 1983 |
Oral iron chelation therapy for thalassaemia: an uncertain scene.
Topics: beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; Humans; Iron Chelating Agents; Iron | 2000 |
The controversial role of deferiprone in the treatment of thalassemia.
Topics: Agranulocytosis; Arthralgia; Clinical Trials as Topic; Deferiprone; Deferoxamine; Drug Therapy, Comb | 2001 |
[Use of desferal in treatment of sideroses of different origin. (Literature review)].
Topics: Anemia; Anemia, Aplastic; Anemia, Sideroblastic; Animals; Bile; Child, Preschool; Deferoxamine; Hemo | 1968 |
4 trials available for deferoxamine and Liver Cirrhosis
| Article | Year |
|---|---|
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2009 |
Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.
Topics: Adolescent; Bone Marrow Transplantation; Chelation Therapy; Child; Combined Modality Therapy; Defero | 1997 |
Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Biopsy; Child; Deferiprone; Deferoxamine; Disease Progression; | 1998 |
Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.
Topics: Biopsy; Blood Transfusion; Chelating Agents; Child; Deferoxamine; Diethylamines; Female; Humans; Iro | 1974 |
73 other studies available for deferoxamine and Liver Cirrhosis
| Article | Year |
|---|---|
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; | 2017 |
Effects of iron chelating agent on Schistosoma mansoni infected murine model.
Topics: Animals; Deferoxamine; Disease Models, Animal; Granuloma; Iron Chelating Agents; Liver Cirrhosis; Li | 2019 |
Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis.
Topics: Adult; Animals; Chemokine CCL2; Deferoxamine; Diet, Fat-Restricted; Female; Femur; Ferric Compounds; | 2019 |
ESR evidence for in vivo formation of free radicals in tissue of mice exposed to single-walled carbon nanotubes.
Topics: Animals; Antioxidants; Bronchoalveolar Lavage Fluid; Cytokines; Deferoxamine; Electron Spin Resonanc | 2014 |
Thalassemia major between liver and heart: Where we are now.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Child, Preschool; Cohort Studies; Deferiprone; Deferoxam | 2015 |
Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapy.
Topics: Animals; Antiviral Agents; Concanavalin A; Deferoxamine; Interferon alpha-2; Interferon-alpha; Iron; | 2015 |
Calcium channel blockers ameliorate iron overload-associated hepatic fibrosis by altering iron transport and stellate cell apoptosis.
Topics: Animals; Apoptosis; Calcium Channel Blockers; Cell Line; Collagen; Deferoxamine; Diltiazem; Hepatic | 2016 |
Deferoxamine alleviates liver fibrosis induced by CCl4 in rats.
Topics: Animals; Carbon Tetrachloride; Deferoxamine; Liver Cirrhosis; Male; Oxidative Stress; Random Allocat | 2016 |
Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease.
Topics: Deferasirox; Deferoxamine; Hepatitis C; Humans; Hypertension, Portal; Iron Overload; Liver Cirrhosis | 2018 |
Liver transplantation from a deceased donor with β-thalassemia intermedia is not contraindicated: A case report.
Topics: beta-Thalassemia; Chelating Agents; Chelation Therapy; Child; Contraindications; Deferoxamine; Femal | 2017 |
Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease.
Topics: Alanine Transaminase; Anemia, Sickle Cell; Area Under Curve; Child; Deferoxamine; Ferritins; Humans; | 2010 |
Incidence of hepatocellular carcinoma in a thalassemia unit.
Topics: Adult; Aged; Antibodies; Carcinoma, Hepatocellular; Chelation Therapy; Deferoxamine; Female; Hepatit | 2010 |
[An older female patient with refractory anemia and hemochromatosis].
Topics: Aged; Anemia, Sideroblastic; Colonic Polyps; Deferoxamine; Diagnosis, Differential; Female; Ferritin | 2002 |
THE TREATMENT OF HAEMOCHROMATOSIS WITH DESFERRIOXAMINE.
Topics: Anemia; Anemia, Macrocytic; Deferoxamine; Diabetes Mellitus; Ferritins; Hemochromatosis; Hemoglobins | 1963 |
DESFERRIOXAMINE EFFECT ON IRON EXCRETION IN HEMOCHROMATOSIS.
Topics: Deferoxamine; Hemochromatosis; Hemosiderosis; Humans; Iron; Iron Chelating Agents; Iron Isotopes; Le | 1964 |
[INFLUENCE OF DESFERRIOXAMINE ON THE URINARY ELIMINATION OF IRON IN NORMAL AND PATHOLOGICAL SUBJECTS].
Topics: Anemia; Deferoxamine; Duodenal Ulcer; Hemochromatosis; Humans; Hydroxamic Acids; Hypersplenism; Iron | 1964 |
[PRELIMINARY RESULTS ON THE USE OF DESFERRIOXAMINE IN POLYCYTHEMIA].
Topics: Alcoholism; Biomedical Research; Deferoxamine; Humans; Hydroxamic Acids; Iron; Liver Cirrhosis; Poly | 1963 |
[ERYTHROBLASTOPHTHISIS].
Topics: Adrenal Cortex Hormones; Androgens; Blood Cell Count; Blood Transfusion; Deferoxamine; Electrocardio | 1964 |
[A NEW TEST FOR ASCERTAINMENT OF STATES OF SIDEROSIS: THE DESFERRIOXAMINE TEST. PRELIMINARY RESULTS].
Topics: Anemia; Anemia, Hypochromic; Biomedical Research; Deferoxamine; Hematologic Diseases; Hemochromatosi | 1964 |
[RESEARCH ON DESFERRIOXAMINE B. 3. THE CLINICAL USE OF DESFERRIOXAMINE B].
Topics: Anemia; Anemia, Hemolytic; Anemia, Macrocytic; Deferoxamine; Hematologic Diseases; Hemochromatosis; | 1964 |
TREATMENT OF PRIMARY AND SECONDARY HEMOCHROMATOSIS AND ACUTE IRON POISONING WITH A NEW POTENT IRON ELIMINATING AGENT (DESFERRIOXAMINE B-DFOM).
Topics: Anemia; Anemia, Aplastic; Anemia, Hemolytic; Anemia, Macrocytic; Deferoxamine; Guinea Pigs; Heavy Me | 1964 |
[SIDERURIA INDUCED BY A NEW CHELATING AGENT: DESFERRIOXAMINE].
Topics: Alcoholism; Chelating Agents; Deferoxamine; Hemochromatosis; Humans; Iron; Liver Cirrhosis; Toxicolo | 1964 |
[DESFERRIOXAMINE (DF) AND DIETHYLENE TRIAMINE PENTA-ACETIC ACID TRISODIUM CALCIUM SALT (CA DTPA NA3) IN SIDEROSIS. 2].
Topics: Anemia; Anemia, Hypochromic; Blood Transfusion; Calcium; Chelating Agents; Deferoxamine; Drug Therap | 1965 |
CHRONIC LIVER DISEASE AND IRON-STORAGE IN THE LIVER.
Topics: Deferoxamine; Hemochromatosis; Hepatitis; Hepatitis A; Humans; Iron; Liver Cirrhosis | 1964 |
IRON CHELATION WITH DEFEROXAMINE IN HEPATIC DISEASE.
Topics: Ammonium Chloride; Biological Transport; Deferoxamine; Fluids and Secretions; Gene Expression Regula | 1965 |
Complications of beta-thalassemia major in North America.
Topics: Adolescent; Adult; Age Factors; beta-Thalassemia; Child; Child, Preschool; Cross-Sectional Studies; | 2004 |
Type 3 hemochromatosis and beta-thalassemia trait.
Topics: Adult; Amino Acid Substitution; beta-Thalassemia; Biopsy; Cardiomyopathy, Dilated; Chelation Therapy | 2004 |
Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy.
Topics: Adolescent; Adult; Anemia, Diamond-Blackfan; Anemia, Sickle Cell; beta-Thalassemia; Biopsy; Blood Tr | 2005 |
Bone marrow transplantation in adults with thalassemia: Treatment and long-term follow-up.
Topics: Adolescent; Adult; Azathioprine; Bone Marrow Transplantation; Busulfan; Chelation Therapy; Clinical | 2005 |
Iron burden and liver fibrosis decrease during a long-term phlebotomy program and iron chelating treatment after bone marrow transplantation.
Topics: Adolescent; Anemia, Sideroblastic; Biomarkers; Bone Marrow Transplantation; Chelation Therapy; Combi | 2006 |
Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Topics: Adolescent; Adult; Alanine Transaminase; beta-Thalassemia; Biomarkers; Biopsy; Chelation Therapy; Ch | 2006 |
Attenuation of acute and chronic liver injury in rats by iron-deficient diet.
Topics: Acute Disease; Animals; Apoptosis; Chemokine CCL2; Chronic Disease; Deferoxamine; Hepatocytes; Inter | 2008 |
Idiopathic hemochromatosis. II. Diagnosis and treatment.
Topics: Deferoxamine; Hemochromatosis; Hemosiderin; Humans; Iron; Iron Chelating Agents; Liver Cirrhosis | 1967 |
Cirrhosis with secondary siderosis or primary haemochromatosis.
Topics: Alcoholism; Deferoxamine; Diagnosis, Differential; Hemochromatosis; Humans; Iron; Iron Isotopes; Liv | 1967 |
Treatment of iron storage disorders.
Topics: Anemia; Deferoxamine; Hemochromatosis; Humans; Iron; Liver Cirrhosis; Porphyrias; Skin Diseases; Tha | 1980 |
Liver iron overload and liver fibrosis in thalassemia.
Topics: Adolescent; Adult; Chelation Therapy; Child; Child, Preschool; Combined Modality Therapy; Deferoxami | 1993 |
Long-term intraperitoneal deferoxamine for hemochromatosis.
Topics: Adult; Cardiomyopathies; Deferoxamine; Female; Hemochromatosis; Humans; Injections, Intraperitoneal; | 1996 |
Iron chelation with oral deferiprone in patients with thalassemia.
Topics: beta-Thalassemia; Biopsy; Deferiprone; Deferoxamine; Ferritins; Humans; Iron Chelating Agents; Iron | 1998 |
Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients.
Topics: Adolescent; Adult; beta-Thalassemia; Chelating Agents; Child; Deferoxamine; Diabetes Mellitus, Type | 1998 |
Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adult; Arrhythmias, Cardiac; beta-Thalassemia; Chela | 2000 |
Liver disease in transfusion dependent thalassaemia major.
Topics: Adolescent; Adult; Alanine Transaminase; Analysis of Variance; beta-Thalassemia; Biopsy; Child; Chil | 2002 |
Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Biopsy; Bone Marrow Transplantation; Child; Combined Modality T | 2002 |
Summaries for patients. Reversibility of liver scarring in patients who are cured of thalassemia.
Topics: Adolescent; Adult; Antiviral Agents; Bone Marrow Transplantation; Child; Combined Modality Therapy; | 2002 |
Treatment of iron overload in adults with continuous parenteral desferrioxamine.
Topics: Adult; Aged; Ascorbic Acid; Biopsy, Needle; Deferoxamine; Female; Ferritins; Hemosiderosis; Humans; | 1977 |
Deferoxamine-chelatable iron in hemochromatosis and other disorders of iron overload.
Topics: Adult; Anemia; Chronic Disease; Deferoxamine; Hemochromatosis; Humans; Iron; Iron Chelating Agents; | 1978 |
[Desferrioxamine in the diagnosis of hypo-, normo-, and hypersiderotic hyposideremia].
Topics: Adult; Aged; Anemia, Hypochromic; Arthritis, Rheumatoid; Breast Neoplasms; Deferoxamine; Duodenal Ul | 1977 |
Idiopathic hemochromatosis: case report of a patient presenting with neurologic symptoms.
Topics: Aged; Deferoxamine; Diabetes Mellitus; Female; Heart Failure; Hemochromatosis; Humans; Iron; Liver C | 1977 |
Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia.
Topics: Adolescent; Adult; Age Factors; Biopsy; Child; Child, Preschool; Deferoxamine; Humans; Iron; Iron Ch | 1975 |
Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine.
Topics: Adolescent; Adult; Child; Deferoxamine; Female; Ferritins; Hepatitis; Hepatitis B Core Antigens; Hep | 1987 |
A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study.
Topics: Adolescent; Adult; Child; Child, Preschool; Deferoxamine; Growth; Heart Diseases; Humans; Iron; Live | 1988 |
Comparison between serum ferritin and computed tomographic densities of liver, spleen, kidney and pancreas in beta-thalassaemia major.
Topics: Blood Transfusion; Child; Child, Preschool; Deferoxamine; Ferritins; Humans; Liver; Liver Cirrhosis; | 1987 |
Assessment of body-iron stores in cirrhosis and haemochromatosis with the differential ferrioxamine test.
Topics: Adolescent; Adult; Aged; Chelating Agents; Deferoxamine; Diagnosis, Differential; Female; Hemochroma | 1967 |
Iron metabolism by reticuloendothelial cells in vitro. Physical and chemical conditions, lipotrope deficiency, and acute inflammation.
Topics: Animals; Ascorbic Acid; Cobalt; Copper; Cysteine; Dactinomycin; Deferoxamine; Dinitrophenols; Edetic | 1969 |
[Comparative studies on the efficacy of chelating agents in experimental iron storage disease in the rat].
Topics: Animals; Body Weight; Chelating Agents; Deferoxamine; Female; Hemochromatosis; Iron; Liver; Liver Ci | 1967 |
[Indications for treatment of chronic hepatitis and liver cirrhosis and their complications. 1. Treatment of chronic hepatitis and liver cirrhosis].
Topics: Azathioprine; Cholecalciferol; Chronic Disease; Deferoxamine; Glucocorticoids; Hepatitis; Humans; Li | 1974 |
Primary hemochromatosis: easily missed cause of cirrhosis, diabetes and heart failure.
Topics: Age Factors; Aged; Blood Cell Count; Bloodletting; Deferoxamine; Diabetes Mellitus; Female; Heart Fa | 1973 |
[Temporary blindness in hemochromatosis].
Topics: Biopsy; Blindness; Deferoxamine; Hemochromatosis; Humans; Injections, Intramuscular; Liver; Liver Ci | 1974 |
[Disorders of iron metabolism in liver patients].
Topics: Adult; Anemia; Biopsy; Deferoxamine; Feces; Female; Hemochromatosis; Humans; Iron; Iron Isotopes; Li | 1966 |
[Idiopathic hemochromatosis. Therapeutics].
Topics: Alcoholism; Bloodletting; Chelating Agents; Deferoxamine; Edetic Acid; Hemochromatosis; Humans; Live | 1967 |
[Regulation of iron metabolism].
Topics: Anemia, Hypochromic; Animals; Deferoxamine; Edetic Acid; Humans; Intestinal Absorption; Intestinal M | 1967 |
Diagnosis of iron storage disease with desferrioxamine (Desferal test).
Topics: Anemia, Macrocytic; Anemia, Sickle Cell; Deferoxamine; Female; Hemochromatosis; Hemosiderosis; Human | 1964 |
[Contribution to the study of intestinal absorption of inorganic and dietary iron by means of Fe59 in healthy subjects, patients with hemochromatosis and cirrhosis, before and after treatment with Desferal].
Topics: Deferoxamine; Hemochromatosis; Humans; Intestinal Absorption; Iron; Iron Isotopes; Liver Cirrhosis | 1967 |
Evaluation of storage iron by chelates.
Topics: Anemia; Animals; Bone Marrow; Deferoxamine; Feces; Hemochromatosis; Humans; Iron; Iron Isotopes; Liv | 1968 |
[Use of desferal and some data on hemosiderosis in hypo- and aplastic anemias].
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Chronic Disease; Deferoxamine; Female; Hemochrom | 1968 |
[Pathologic deposit of iron in liver cirrhosis].
Topics: Adolescent; Adult; Aged; Deferoxamine; Humans; Iron; Liver Cirrhosis; Liver Function Tests; Middle A | 1969 |
Clinical and laboratory studies on the action of desferrioxamine.
Topics: Animals; Deferoxamine; Diet; Feces; Ferritins; Hemochromatosis; Humans; Intestinal Mucosa; Iron; Kid | 1969 |
Differential ferrioxamine test in idiopathic haemochromatosis and transfusional haemosiderosis.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Biopsy; Blood Chemical Analysis; Bloodletting; Deferoxam | 1966 |
Effects of desferrioxamine in patients with iron-loading with a simple method for estimating urinary iron.
Topics: Anemia, Hypochromic; Anemia, Sideroblastic; Deferoxamine; Hemochromatosis; Humans; In Vitro Techniqu | 1966 |
Sideruria following a single dose of desferrioxamine-B as a diagnostic test in iron overload.
Topics: Adult; Anemia, Hemolytic; Blood; Bone Marrow; Deferoxamine; Female; Hemochromatosis; Hemosiderosis; | 1966 |
Iron metabolism in patients with porta-caval shunts.
Topics: Deferoxamine; Erythropoiesis; Humans; Intestinal Absorption; Iron; Iron Isotopes; Liver; Liver Cirrh | 1966 |
Transferrin behaviour in haemochromatosis.
Topics: Deferoxamine; Hemochromatosis; Hemosiderosis; Hepatitis A; Humans; Iron; Liver; Liver Cirrhosis; Mid | 1966 |
[Respective variations of sideremia and sideruria in cirrhotic patients following the desferrioxamine B test].
Topics: Deferoxamine; Hemosiderosis; Humans; Iron; Liver Cirrhosis; Siderosis | 1966 |
[Respective variations of iron in blood and urine in cirrhotic and alcoholic patients after a desferrioxamine test].
Topics: Alcoholism; Deferoxamine; Diagnosis, Differential; Female; Hemochromatosis; Humans; Iron; Liver Cirr | 1966 |